The European Commission has granted orphan medicinal product designation to AIT-CF, a cystic fibrosis treatment from Advanced Inhalation Therapies Ltd.

AIT has ended a Phase 2a trial for AIT-CF testing it as a treatment for cystic fibrosis adult patients. In February 2015, the Company announced that the United States Food and Drug Administration (FDA) granted an Orphan Drug Designation to AIT-CF for adjunctive treatment of cystic fibrosis. Now, the European Commission has followed suit, further supporting the drug’s promising therapeutic benefits.

David Greenberg, the Chief Medical Officer of Advanced Inhalation Therapies, commented in a press release: “AIT-CF potentially affords a significant benefit to CF patients. As a naturally occurring chemical in the body, NO, when inhaled at high concentrations, kills bacteria and fungi in the lungs of CF patients and has shown broad anti-infective activity. The European Orphan Drug Designation for AIT-CF affords additional benefits as we continue to advance its clinical development.”

Read the full story at www.cysticfibrosisnewstoday.com